Share
From Breakthrough to Blockbuster: The Business of Biotechnology
Donald L. Drakeman
(Author)
·
Lisa N. Drakeman
(Author)
·
Nektarios Oraiopoulos
(Author)
·
Oxford University Press, USA
· Hardcover
From Breakthrough to Blockbuster: The Business of Biotechnology - Drakeman, Donald L. ; Drakeman, Lisa N. ; Oraiopoulos, Nektarios
£ 23.84
£ 26.49
You save: £ 2.65
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My WishlistsIt will be shipped from our warehouse between
Thursday, May 16 and
Friday, May 17.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "From Breakthrough to Blockbuster: The Business of Biotechnology"
Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.
